[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356751-105":59,"doc-detail-356751-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-combined-inhibitory-effect-of-butaselen-and-decitabine-against-lung-cancer-cells-mechanistic-in-vitro-study","The combined inhibitory effect of butaselen and decitabine against lung cancer cells - Mechanistic in vitro study","","The study investigates how combining the thioredoxin reductase inhibitor butaselen (BS/BS1801) with the DNA methyltransferase inhibitor decitabine (DAC) affects lung cancer cells in vitro. Human lung cancer cell lines A549 and H1299 were treated and assessed for cytotoxicity, proliferation, apoptosis, and migration, alongside Chou–Talalay synergy-related analyses. Combined treatment increased inhibition of proliferation and migration while elevating apoptosis. Molecular changes included DNMT1 downregulation, decreased Bcl-2/Bax ratio, and increased HOXA9, p21, and E-cadherin, supporting further evaluation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-combined-inhibitory-effect-of-butaselen-and-decitabine-against-lung-cancer-cells-mechanistic-in-vitro-study/356751/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-combined-inhibitory-effect-of-butaselen-and-decitabine-against-lung-cancer-cells-mechanistic-in-vitro-study/356751.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of combining butaselen (BS) and decitabine (DAC)?","Question",{"text":113,"@type":114},"To evaluate whether BS and DAC produce enhanced anti-lung-cancer effects together and to identify the associated molecular mechanisms in vitro.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which lung cancer cell models were used in the experiments?",{"text":118,"@type":114},"Human lung cancer cell lines A549 and H1299 were used as the in vitro models.",{"name":120,"@type":111,"acceptedAnswer":121},"What molecular effects were observed after combined BS + DAC treatment?",{"text":122,"@type":114},"The combination downregulated DNMT1, reduced the Bcl-2/Bax ratio, and upregulated HOXA9, p21, and E-cadherin, coinciding with increased apoptosis and inhibited proliferation/migration.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356751,1790186137,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe combined inhibitory effect of butaselen and decitabine against lung cancer cells  \nYifan Chen1,2,3,4,7, Chutong Lin5,7, Yingyuan Lu6,7, Huihui Zeng6, Lixiang Xue1,2,3 & Guangliang Qiang5􀀍  \nThe DNA methyltransferase inhibitor decitabine (DAC) is clinically approved for hematologic malignancies, but its efficacy in solid tumors, including lung cancer, remains limited. This study aimed to investigate the combined effects ofthe thioredoxin reductase (TrxR) inhibitor butaselen (BS/ BS1801) and DAC on lung cancer cells in vitro. Human lung cancer cell lines (A549 and H1299) were used as an in vitro model. Cytotoxicity was assessed using the CCK‑8 assay. Combination index (CI) and dose‑reduction index (DRI) analyses were performed to evaluate the combined effects of BS and  \nDAC. Cell proliferation was detected by colony formation assay, apoptosis by Annexin V/PI staining with flow cytometry, and migration by wound healing assay. Protein expression levels of DNMT1, Bcl‑2, Bax, HOXA9, p21, and E‑cadherin were determined by western blotting. The combination of BS and DAC resulted in enhanced inhibition of proliferation and migration, and increased induction of apoptosis compared with either agent alone inA549 and H1299 cells, under specific ratio and time conditions. The combined treatment was associated with downregulation of DNMT1, a reduced Bcl‑2/ Bax ratio, and upregulation of HOXA9, p21, and E‑cadherin. These preclinical findings suggest that the combination of BS and DAC represents a mechanistically rationalized and promising therapeutic strategy for lung cancer that warrants further evaluation in in vivo models and early‑phase clinical trials.  \nKeywords Condition‑dependent synergy, Decitabine (DAC), Butaselen (BS/BS1801), Apoptosis, Lung cancer  \nLung cancer remains one of the leading causes of cancer‑related mortality worldwide, with a five‑year survival rate below 20%1,2. Despite advances in targeted therapy and immunotherapy, effective treatments for the majority of patients remain an unmet need. Epigenetic dysregulation, particularly aberrant DNA methylation, is a hallmark of lung cancer and contributes to the silencing of tumor suppressor genes3,4. This has prompted interest in epigenetic therapies, among which decitabine (DAC), a DNA methyltransferase inhibitor, has been clinically approved for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)5–8. In solid tumors, including lung cancer, DAC as a single agent exhibits only modest antitumor activity9–11. Low doses may induce DNA damage without sufficient cytotoxicity, while dose escalation to achieve therapeutic efficacy is often accompanied by myelosuppression and neurotoxicity12, 13. Accordingly, combination strategies that enhance DAC’s efficacy while minimizing its toxicity have garnered considerable interest14.  \nButaselen (BS/BS1801, 2‑bis[2‑(1,2‑benzisothiazol‑2(2H)‑ketone)] butane) is an organic selenium compound that specifically targets the Trx system. It was independently designed and synthesized by our group15. Our previous studies have demonstrated its antitumor activity in liver cancer, lung cancer, and glioma16–18 , as well as synergistic effects with cisplatin and anti‑PD‑1 immunotherapy in preclinical liver cancer models19,20. The absorption, distribution, metabolism, and excretion of BS have been characterized in prior studies involving humans and rats21,22. BS is currently under Phase I clinical evaluation for safety in healthy volunteers (ChiCTR2100045813) and for anti‑tumor activity in high‑grade gliomas (CTR20234234) . In addition, BS has  \n1Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. 2Cancer Center, Peking University Third Hospital, Beijing, China. 3Peking University Third Hospital, Beijing, China. 4National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China.","cbCaiq39jzyXWFWl","https://ap.wps.com/l/cbCaiq39jzyXWFWl","pdf",1749308,"English","# Introduction\n# Materials and methods\n## Chemicals and reagents\n## Cell culture, cell viability assay and Chou–Talalay analyses\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"What was the main goal of combining butaselen (BS) and decitabine (DAC)?\",\"answer\":\"To evaluate whether BS and DAC produce enhanced anti-lung-cancer effects together and to identify the associated molecular mechanisms in vitro.\"},{\"question\":\"Which lung cancer cell models were used in the experiments?\",\"answer\":\"Human lung cancer cell lines A549 and H1299 were used as the in vitro models.\"},{\"question\":\"What molecular effects were observed after combined BS + DAC treatment?\",\"answer\":\"The combination downregulated DNMT1, reduced the Bcl-2/Bax ratio, and upregulated HOXA9, p21, and E-cadherin, coinciding with increased apoptosis and inhibited proliferation/migration.\"}]","The combined inhibitory effect of butaselen and decitabine against lung cancer cells - Mechanistic in vitro study | PDF",1790127108,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5113cbab7eec67b1e1d37ec1ba6cc06.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7346daf6cbd3a3a6bdc4721304ac186a.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceba3b3edf1e36989f03784737fe5e02.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f99720603f76535ef5383fce6218f5e.webp",980,1287]